Compare Abeona Therapeutics Inc (ABEO) vs iShares 20 Plus Year Treasury Bond ETF (TLT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs iShares 20 Plus Year Treasury Bond ETF — how do they compare? Abeona Therapeutics Inc trades at $6.72 (market cap $373.32M), while iShares 20 Plus Year Treasury Bond ETF trades at $84.32. The key difference: Abeona Therapeutics Inc is trading nearer its 52-week high, iShares 20 Plus Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.
| ABEO | TLT | |
|---|---|---|
Market Cap | $373.32M | — |
Sector | Health | — |
52-Week High | $7.23 | $92.06 |
52-Week Low | $4.17 | $83.02 |
Enterprise Value | $228.22M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
TLT, the iShares 20+ Year Treasury Bond ETF, trades at $84.55, down 1.12% on the day, reflecting ongoing bearish pressure in the long-duration Treasury market. Technical indicators are predominantly bearish, with moving averages signaling a strong sell, while oscillators remain neutral. The fund has faced significant drawdowns recently, losing nearly 48% since 2020, but now offers higher starting yields, attracting investor attention amid shifting Fed policy expectations and inflation concerns.
The outlook for TLT hinges on Federal Reserve interest rate decisions and inflation trends. Opportunities exist for yield-seeking investors due to elevated distributions, but risks include potential further rate hikes, prolonged high inflation, and interest rate sensitivity. Market sentiment is mixed, with some analysts seeing value after the steep decline, while others caution about duration risk in a volatile macroeconomic environment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About iShares 20 Plus Year Treasury Bond ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index, and it will invest at least 90% of its assets in US Treasury securities that the advisor believes will help the fund track the underlying index. The underlying index measures the performance of public obligations of the US Treasury that have a remaining maturity greater than or equal to twenty years.
Read more on TLT →
